RNase L Antibody (2E9) [Janelia Fluor® 646]

Sold under license from the Howard Hughes Medical Institute, Janelia Research Campus.

RNase L is a virally induced endoribonuclease that is also the terminal factor of the anti-viral action of interferon. Activation of RNase L results in inhibition of viral proliferation through total RNA degradation. Activation of RNase L has also been determined to degrade RNA, thus, initiating a cellular stress response, inducing apoptosis. Since mutations in RNase L relate to an increased incidence of prostate cancer, the activation of RNase L is thought to function in counteracting prostate cancer, via apoptosis.

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Array NB100-351JF646

• RNase L Antibodies
• RNase L ELISA Kits
• RNase L Protein